Episode Details

The FDA recently cleared TumorSight Risk, an AI software that analyzes MRI and clinical data to predict the 5- and 10-year recurrence risk for breast cancer patients. Maya and Sam unpack the 510(k) summary, exploring the algorithm's impressive negative predictive value, its retrospective validation on 2,129 patients, and what it means for the future of prognostic AI in clinical practice.

Key points

• TumorSight Risk predicts 5- and 10-year recurrence risks for patients with early-stage, HR+/HER2- breast cancer using a proprietary score from 0-100.
• The model demonstrated a 97.0% negative predictive value at 5 years, meaning patients classified as low risk have a high probability of remaining recurrence-free in that window.
• Validation relied on a retrospective study of 2,129 patients diagnosed between 2010 and 2024, proving the need for long-term historical data in prognostic AI.
• The software uses Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) alongside clinical inputs like age, race, and tumor grade.
• The FDA cleared it as a Class II device by finding it substantially equivalent to ArteraAI Breast, even though the predicate used pathology slides rather than MRI data.

Source: TumorSight Risk - U.S. Food and Drug Administration, 2026

This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/predicting-breast-cancer-recurrence-inside-the-fda-clearance-of-tumors-ae3f9f